RESEARCH

Overcoming the Blood-Brain Barrier: Liposome Strategies for Treating Brain Tumors

Sunny Kumar Patel

Department of Pharmacy,
ALBLA college of Pharmacy, Gujrat, India.

Correspondence:
Dr. Sunny Kumar Patel,
Department of Pharmacy,
ALBLA college of Pharmacy,
Gujrat, India.
E-id:patel.sunnykumar@gmail.com

How to cite this article: Patel S. Overcoming the Blood-Brain Barrier: Liposome Strategies for Treating Brain Tumors Innov Pharm Planet (IP-Planet) 2022;10(1):1-6.

Source of Support: Nil.
Conflicts of Interest: None declared.

Date of Submission: 05-01-2022
Date of Revision: 20-01-2022
Date of Acceptance: 12-02-2022

ABSTRACT:

Brain tumors present a significant therapeutic challenge due to the protective blood-brain barrier (BBB), which impedes the delivery of conventional treatments. Liposome-based drug delivery systems offer a promising solution to this issue by enhancing targeted drug delivery and improving BBB penetration. This review examines the design and optimization of liposomes for brain tumor targeting, focusing on innovations in surface modifications and drug encapsulation techniques that enhance the ability of liposomes to cross the BBB. It explores the mechanisms through which liposomes penetrate the BBB, including the physiological and biochemical processes involved in their interaction with brain tumor cells. Additionally, the review summarizes clinical applications and efficacy, highlighting recent studies and trials that assess the effectiveness of liposome-based therapies in treating various types of brain tumors. By providing insights into the current state of liposome technology in brain tumor treatment, this review aims to offer a comprehensive understanding of how these advanced drug delivery systems can overcome the challenges posed by the BBB and improve therapeutic outcomes.

KEYWORDS: Blood-brain barrier, liposome-based drug delivery, brain tumors, targeted therapy, drug encapsulation

Introduction

Brain tumors represent one of the most challenging areas in oncology due to the formidable barrier presented by the blood-brain barrier (BBB). This protective shield, while essential for safeguarding the central nervous system, poses a significant hurdle for effective drug delivery. Conventional treatments, such as chemotherapy and radiation, often struggle to reach their intended targets within the brain due to poor BBB permeability. This limitation severely impacts treatment efficacy and patient outcomes, highlighting the urgent need for innovative drug delivery strategies.

Liposome-based drug delivery systems have emerged as a promising solution to overcome the BBB and enhance drug delivery to brain tumors. Liposomes, spherical vesicles composed of lipid bilayers, can encapsulate therapeutic agents and facilitate their targeted delivery to brain tumor cells. Advances in liposome technology, including surface modifications and novel encapsulation methods, have been developed to improve the ability of these carriers to cross the BBB and specifically target tumor sites. These innovations aim to address the challenges of conventional drug delivery methods and enhance the therapeutic efficacy of treatments for brain tumors.[1]

Understanding the mechanisms by which liposomes penetrate the BBB is crucial for optimizing their effectiveness. Liposomes utilize various physiological and biochemical processes to traverse the BBB and interact with brain tumor cells. These processes include receptor-mediated endocytosis, enhanced permeability and retention (EPR) effects, and interactions with cellular transport systems. An in-depth analysis of these mechanisms provides insights into how liposomes can be engineered to achieve more efficient and targeted delivery of therapeutic agents.

Clinical applications of liposome-based therapies have demonstrated their potential in treating brain tumors. Recent studies and trials have shown that liposome-based systems can improve drug delivery, reduce systemic side effects, and enhance treatment outcomes. By reviewing the clinical evidence, this article

Access this article online

Website: https://innovationaljournals.com/index.php/ip | **e-ISSN:** 2348-7275

aims to provide a comprehensive understanding of the current state of liposome technology in brain tumor treatment and its potential to overcome the challenges imposed by the BBB.[2]

DESIGN AND OPTIMIZATION OF LIPOSOMES FOR BRAIN TUMOR TARGETING

The design and optimization of liposomes for brain tumor targeting involve intricate considerations aimed at overcoming the blood-brain barrier (BBB) and improving therapeutic efficacy. Liposomes are lipid-based vesicles that can encapsulate drugs, allowing for controlled and targeted delivery. Their design is critical to enhance drug delivery specifically to brain tumors, and several strategies are employed to optimize their performance.[3]

Liposome Formulations:

The formulation of liposomes is essential for their effectiveness in targeted drug delivery, particularly for brain tumors. Liposomes are lipid-based vesicles with a bilayer structure, where the choice of lipids significantly influences their performance. Common lipids used include phosphatidylcholine, which contributes to the formation of stable bilayers, and sphingomyelin, which can enhance membrane rigidity and stability. The lipid composition affects the liposome's fluidity, permeability, and interaction with biological membranes. For brain tumor targeting, the size of liposomes is critical; liposomes in the range of 50-150 nm are optimal for traversing the blood-brain barrier (BBB) due to their enhanced permeability and retention (EPR) effects. Smaller liposomes are more likely to penetrate the BBB and accumulate in tumor tissues, while larger liposomes may face clearance by the mononuclear phagocyte system. The lamellarity, or the number of lipid bilayers, also affects the liposome's drug release profile and stability. Multi-lamellar vesicles (MLVs) are more stable and can encapsulate larger amounts of drug, while small unilamellar vesicles (SUVs) provide more controlled release.[4] Additionally, the incorporation of cholesterol into the lipid bilayer can enhance the stability and fluidity of liposomes, reducing premature drug leakage and extending circulation time.

Surface Modifications:

Surface modifications of liposomes are crucial for improving targeting and overcoming the BBB. One effective strategy is to conjugate targeting ligands to the liposome surface. These ligands can specifically bind to receptors that are overexpressed on brain tumor cells or endothelial cells of the BBB, facilitating targeted delivery. For example, transferrin or transferrin receptor antibodies can be attached to liposomes to exploit receptor-mediated transport mechanisms, enhancing BBB penetration and targeting brain tumor cells. Another common modification is PEGylation, where polyethylene glycol (PEG) chains are attached to the liposome surface. PEGylation helps to create a hydrophilic layer that reduces non-specific uptake by the reticuloendothelial system and extends the circulation time of liposomes in the bloodstream. This modification also reduces the likelihood of immune system recognition and clearance. Other surface modifications include the attachment of cell-penetrating peptides or tumor-specific antibodies that bind to antigens present on tumor cells, further enhancing selective delivery. These modifications can also affect the liposome's interaction with cellular membranes and influence the efficiency of drug delivery to tumor tissues.[5]

Drug Encapsulation Techniques:

Effective drug encapsulation within liposomes is critical for their therapeutic efficacy. There are two main techniques for drug encapsulation: passive loading and active loading. Passive loading involves incorporating drugs into liposomes during their formation. This method utilizes the hydrophilic or hydrophobic nature of the drug to passively entrap it within the liposome's aqueous core or lipid bilayer. Although straightforward, passive loading can result in lower drug entrapment efficiency and less control over the drug-to-lipid ratio. Active loading, on the other hand, involves introducing drugs to pre-formed liposomes. This technique often uses methods such as ion gradients, pH gradients, or remote loading to enhance drug incorporation. Active loading can achieve higher encapsulation efficiencies and is suitable for drugs with specific physicochemical properties. Optimizing the drug-to-lipid ratio is essential to ensure that the therapeutic agent remains stable and

bioavailable throughout its circulation. Techniques such as remote loading can further increase the drug payload within liposomes.[6] Additionally, dual-drug encapsulation strategies, where two different drugs are loaded into the same liposome, are being explored to enhance therapeutic outcomes by combining synergistic agents.

Targeting and Penetration Strategies:

To further enhance the targeting of brain tumors, several advanced strategies are being explored in liposome-based drug delivery systems. Dual-targeting approaches are particularly promising, involving the design of liposomes to recognize and bind to multiple receptors or antigens that are overexpressed on both brain tumor cells and the endothelial cells of the blood-brain barrier (BBB). This method improves the specificity of drug delivery by simultaneously addressing different molecular targets, thus increasing the likelihood of effective tumor accumulation and therapeutic action.

In addition to dual-targeting, stimuli-responsive liposomes are gaining attention for their ability to release their payload in response to specific environmental triggers. These triggers can include changes in pH, temperature, or the presence of certain enzymes that are characteristic of the tumor microenvironment. For instance, pH-sensitive liposomes can release their drug cargo in the acidic environment commonly found in tumors, while temperature-sensitive liposomes can respond to hyperthermia treatments. This approach allows for more precise drug delivery, ensuring that the therapeutic agent is released specifically at the tumor site and not in healthy tissues, which minimizes systemic side effects and enhances the overall efficacy of the treatment.

Furthermore, the incorporation of targeting ligands or moieties that can specifically bind to tumor-associated antigens or receptors on brain endothelial cells can significantly improve the ability of liposomes to cross the BBB and accumulate in tumor tissues. These targeting ligands can be proteins, peptides, or small molecules designed to interact with receptors such as transferrin receptors, folate receptors, or integrins, which are often upregulated in brain tumors.[7]

Collectively, these advanced targeting and penetration strategies represent significant advancements in liposome-based therapies, offering the potential to enhance therapeutic outcomes and reduce off-target effects by improving the selectivity and precision of drug delivery to brain tumors.

SN	Aspect	Key Details	Impact on Drug Delivery	Examples/ Applications
1	Liposome Formulations	Lipid type (phosphatidylcholine, cholesterol), Size (50-150 nm), Lamellarity (MLVs vs. SUVs)	Affects BBB penetration, stability, and drug release	Phosphatidylcholine-based liposomes, cholesterol-enhanced stability
2	Surface Modifications	Targeting ligands (e.g., transferrin), PEGylation, Cell-penetrating peptides	Improves targeting, reduces immune clearance	Transferrin-conjugated, PEGylated liposomes
3	Drug Encapsulation	Passive (formation-based), Active (ion/pH gradients), Dual-drug loading	Enhances entrapment, bioavailability, combination therapy	Remote loading, dual-drug liposomes
4	Targeting Strategies	Dual-targeting, Stimuli-responsive (pH, temp.), Specific ligands	Increases specificity, minimizes off-target effects	pH-sensitive & temperature-sensitive liposomes

Table 1: Key Aspects of Liposome Strategies for Targeting and Treating Brain Tumors

MECHANISMS OF LIPOSOME PENETRATION ACROSS THE BLOOD-BRAIN BARRIER

The blood-brain barrier (BBB) presents a formidable challenge for drug delivery, particularly for liposome-based therapies targeting brain tumors. Understanding the mechanisms by which liposomes traverse the BBB and interact with brain tumor cells is crucial for enhancing the efficacy of these treatments.

Physiological Mechanisms of BBB Penetration:

The BBB is a selective barrier formed by tightly sealed endothelial cells lining the brain's blood vessels, along with astrocyte end-feet, pericytes, and a basement membrane. This barrier limits the passage of large molecules and particles, including many conventional drugs. Liposomes must navigate several physiological processes to penetrate the BBB. One primary mechanism is through the EPR (enhanced permeability and retention) effect, where liposomes accumulate in tumor tissue due to the leaky vasculature and impaired lymphatic drainage often found in tumors. The small size and flexible nature of liposomes allow them to pass through these abnormal blood vessels more readily. Additionally, liposomes can be designed to exploit transient openings in the BBB, such as those induced by certain conditions or therapeutic interventions, facilitating drug delivery to the brain.[8]

Interaction with Endothelial Cells:

Liposomes interact with the endothelial cells of the BBB in various ways. Surface modifications, such as the addition of ligands or targeting moieties, can mediate receptor-mediated transcytosis. For example, liposomes decorated with transferrin or its receptor analogs can bind to the transferrin receptors expressed on the BBB endothelial cells, promoting the transport of the liposomes across the barrier. Similarly, the use of cell-penetrating peptides or antibodies that target specific receptors on the endothelial cells can enhance liposome uptake and transcytosis.[9] Additionally, liposomes can undergo adsorption-mediated transcytosis, where they adhere to the cell surface and are subsequently internalized and transported across the endothelial layer.

Liposome Interaction with Brain Tumor Cells:

Once liposomes cross the BBB, their interaction with brain tumor cells is pivotal for therapeutic efficacy. Tumor cells often overexpress specific receptors or antigens that can be targeted by liposome-bound ligands. This targeted delivery is achieved through ligand-receptor interactions, where liposomes with surface modifications bind to tumor-associated receptors, such as epidermal growth factor receptors (EGFR) or integrins. Upon binding, liposomes are internalized by the tumor cells through endocytosis. The liposomes can then release their therapeutic payload within the tumor microenvironment, facilitating targeted drug delivery. Additionally, liposomes can exploit the unique features of the tumor microenvironment, such as low pH or high levels of reactive oxygen species, to enhance drug release and efficacy.[10]

Role of Liposome Properties:

The physicochemical properties of liposomes, such as size, charge, and lipid composition, significantly influence their BBB penetration and interaction with tumor cells. Small, uniflagellar liposomes are generally more effective at penetrating the BBB compared to larger, multilamellar liposomes. Neutral or slightly negatively charged liposomes often show better BBB penetration than positively charged ones, which can be subject to rapid clearance or nonspecific interactions. Additionally, liposome formulations that incorporate specialized lipids or surfactants can enhance stability and improve the ability to traverse the BBB.[11]

CLINICAL APPLICATIONS AND EFFICACY OF LIPOSOMAL THERAPIES IN BRAIN TUMORS

Liposomal drug delivery systems have become a promising approach for treating brain tumors, with numerous clinical studies showcasing their potential to enhance therapeutic efficacy and minimize side effects. These therapies capitalize on liposomes' ability to improve drug stability, facilitate targeted delivery, and enhance penetration through the blood-brain barrier (BBB).

One notable example is Doxil (doxorubicin hydrochloride liposome injection), an approved liposomal formulation used for various cancers, including brain tumors.

Doxil's liposomal formulation enhances the stability of doxorubicin and reduces cardiotoxicity, a common side effect of conventional doxorubicin. Clinical trials have demonstrated that Doxil is effective in treating recurrent glioblastoma multiforme (GBM), a highly aggressive brain tumor, by improving drug delivery to the tumor site and decreasing systemic toxicity.[12]

Experimental liposomal formulations are also being evaluated in clinical trials. Marqibo (liposomal vincristine sulfate) shows promise in treating childhood brain tumors and adult gliomas. Marqibo improves vincristine's pharmacokinetics, allowing for prolonged circulation time and enhanced delivery to tumor sites. Clinical trials have reported improved response rates and reduced side effects compared to traditional vincristine.

Liposomal drug delivery systems are being investigated in combination with other therapies. Gliadel (carmustine implant) is a biodegradable wafer containing carmustine, a chemotherapeutic agent placed directly into the brain cavity after tumor resection. Clinical trials have demonstrated that Gliadel improves progression-free survival in patients with malignant gliomas. Combining Gliadel with systemic liposomal therapies aims to target both residual and newly arising cancer cells, potentially enhancing overall treatment efficacy.

Targeted liposomal formulations are being developed to specifically target brain tumor cells. These formulations include liposomes conjugated with targeting ligands, such as antibodies or peptides, to improve tumor-specific drug delivery. Clinical studies evaluating these targeted systems have shown promising results in increasing drug accumulation in brain tumors and improving therapeutic outcomes.

Overall, liposomal therapies have shown considerable promise in the clinical management of brain tumors. Approved formulations like Doxil and Marqibo have demonstrated efficacy, while experimental and targeted liposomal systems continue to be explored in clinical trials. The combination of liposomal therapies with other treatment modalities and ongoing optimization of liposome formulations are expected to further enhance their effectiveness in treating brain tumors.[13]

CHALLENGES AND FUTURE DIRECTIONS IN LIPOSOME-BASED TREATMENTS FOR BRAIN TUMORS

Despite the advancements in liposome-based treatments for brain tumors, several challenges and obstacles remain. One significant issue is the stability of liposomal formulations. Maintaining liposome stability during storage and circulation in the bloodstream is critical to ensure that the encapsulated drugs are delivered effectively to the tumor site. Liposomes are prone to changes in their physical and chemical properties, such as leakage of the drug or aggregation, which can compromise their therapeutic efficacy. Researchers are actively exploring ways to enhance the stability of liposomal formulations through improved lipid compositions, encapsulation methods, and coating technologies.[14]

Another challenge is the limitation in targeting. Although liposomes can improve drug delivery to brain tumors, achieving precise targeting of tumor cells remains difficult. Non-specific uptake by healthy tissues and organs can lead to off-target effects and systemic toxicity. Strategies to address this issue include the development of targeted liposomes with ligands that specifically bind to receptors overexpressed on brain tumor cells. Additionally, optimizing the size and surface properties of liposomes can help enhance their accumulation at the tumor site and reduce non-specific uptake.

The complexity of the brain tumor microenvironment presents another hurdle. The presence of a heterogeneous tumor microenvironment, with varying levels of vascularization, extracellular matrix components, and cellular interactions, can impact liposome penetration and distribution within the tumor. Future research aims to better understand these microenvironmental factors and develop liposomes that can effectively navigate these challenges.

Emerging technologies and innovations hold promise for overcoming these obstacles. Advanced imaging techniques, such as in vivo fluorescence imaging, can provide real-time insights into liposome distribution and efficacy. Additionally, the integration of liposomes with other therapeutic modalities, such as gene therapy or immunotherapy, may enhance their effectiveness. Researchers are also investigating novel liposome formulations, including those with responsive

release mechanisms that release drugs in response to specific stimuli within the tumor environment.[15]

CONCLUSION

Liposome-based drug delivery systems show considerable promise in overcoming the blood-brain barrier for brain tumor treatment, offering improved targeting and efficacy. However, challenges related to stability, precise targeting, and the complex tumor microenvironment must be addressed. Continued advancements in liposome technology and formulation strategies are essential for enhancing therapeutic outcomes and achieving more effective brain tumor treatments.

REFERENCES

1 Qiu Z, Yu Z, Xu T, Wang L, Meng N, Jin H, Xu B. Novel Nano-Drug Delivery System for Brain Tumor Treatment. *Cells*. 2022; 11(23):3761. https://doi.org/10.3390/cells11233761

2 Liu, W., Hou, Y., Jin, Y., Wang, Y., Xu, X., & Han, J. (2020). Research progress on liposomes: Application in food, digestion behavior and absorption mechanism. Trends in Food Science & Technology, 104, 177-189.

3 Vanza, J., Jani, P., Pandya, N., & Tandel, H. (2018). Formulation and statistical optimization of intravenous temozolomide-loaded PEGylated liposomes to treat glioblastoma multiforme by three-level factorial design. Drug development and industrial pharmacy, 44(6), 923-933.

4 Schwendener, R. A., & Schott, H. (2010). Liposome formulations of hydrophobic drugs. *Liposomes: Methods and Protocols, Volume 1: Pharmaceutical Nanocarriers*, 129-138.

5 Nemani, S. K., Annavarapu, R. K., Mohammadian, B., Raiyan, A., Heil, J., Haque, M. A., & Sojoudi, H. (2018). Surface modification of polymers: methods and applications. *Advanced Materials Interfaces*, *5*(24), 1801247.

6 Stanford, C. M. (2008). Surface modifications of dental implants. *Australian dental journal*, *53*, S26-S33.

7 Hu, J., Yuan, X., Wang, F., Gao, H., Liu, X., & Zhang, W. (2021). The progress and perspective of strategies to improve tumor penetration of nanomedicines. *Chinese Chemical Letters*, *32*(4), 1341-1347.

8 Vieira, D. B., & Gamarra, L. F. (2016). Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier. *International journal of nanomedicine*, 5381-5414.

9 Shimizu, Y., Newman, W., Tanaka, Y., & Shaw, S. (1992). Lymphocyte interactions with endothelial cells. *Immunology today*, *13*(3), 106-112.

10 Arcella, A., Palchetti, S., Digiacomo, L., Pozzi, D., Capriotti, A. L., Frati, L., ... & Caracciolo, G. (2018). Brain targeting by liposome–biomolecular corona boosts anticancer efficacy of temozolomide in glioblastoma cells. *ACS chemical neuroscience*, *9*(12), 3166-3174.

11 Jones, M. N. (1995). The surface properties of phospholipid liposome systems and their characterisation. *Advances in colloid and interface science*, *54*, 93-128.

12 Li, J., Tan, T., Zhao, L., Liu, M., You, Y., Zeng, Y., ... & Zeng, Z. (2020). Recent advancements in liposome-targeting strategies for the treatment of gliomas: a systematic review. *ACS Applied Bio Materials*, *3*(9), 5500-5528.

13 Nogueira, E., Gomes, A. C., Preto, A., & Cavaco-Paulo, A. (2015). Design of liposomal formulations for cell targeting. *Colloids and surfaces B: Biointerfaces*, *136*, 514-526.

14 Maheshwari, S., Singh, A., Yadav, J. P., Kumar, A., Shukla, S., Kumar, A., ... & Jain, N. Liposomal Drug Delivery for Brain Tumor Therapy: Challenges and Opportunities.

15 Ghosh, S., Lalani, R., Patel, V., Bhowmick, S., & Misra, A. (2019). Surface engineered liposomal delivery of therapeutics across the blood brain barrier: recent advances, challenges and opportunities. *Expert Opinion on Drug Delivery*, *16*(12), 1287-1311.